Trial Profile
A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and Its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Epelsiban (Primary)
- Indications Infertility
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 21 Apr 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov
- 19 Oct 2014 Planned End Date changed from 1 Nov 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 19 Oct 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.